Ainos, Inc. (AIMD) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in San Diego, CA, United States. The current CEO is Chun-Hsien Tsai.
AIMD has IPO date of 2021-01-08, 44 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $7.06M.
Ainos, Inc., a healthcare company, engages in the developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. Ainos, Inc. was incorporated in 1984 and is based in San Diego, California.
